Medical - Healthcare Information Services
Compare Stocks
5 / 10Stock Comparison
CERT vs VEEV vs MEDP vs IQV vs DOCS
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Information Services
Medical - Diagnostics & Research
Medical - Diagnostics & Research
Medical - Healthcare Information Services
CERT vs VEEV vs MEDP vs IQV vs DOCS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Healthcare Information Services | Medical - Healthcare Information Services | Medical - Diagnostics & Research | Medical - Diagnostics & Research | Medical - Healthcare Information Services |
| Market Cap | $1.03B | $27.35B | $12.24B | $30.32B | $5.24B |
| Revenue (TTM) | $419M | $3.20B | $2.68B | $16.63B | $638M |
| Net Income (TTM) | $-2M | $909M | $460M | $1.39B | $239M |
| Gross Margin | 61.5% | 75.5% | 29.1% | 26.1% | 89.7% |
| Operating Margin | 5.0% | 28.7% | 21.0% | 13.9% | 37.4% |
| Forward P/E | 14.1x | 19.0x | 25.2x | 14.1x | 16.8x |
| Total Debt | $11M | $96M | $250M | $16.17B | $12M |
| Cash & Equiv. | $189M | $1.42B | $497M | $1.98B | $210M |
CERT vs VEEV vs MEDP vs IQV vs DOCS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 21 | May 26 | Return |
|---|---|---|---|
| Certara, Inc. (CERT) | 100 | 22.3 | -77.7% |
| Veeva Systems Inc. (VEEV) | 100 | 54.1 | -45.9% |
| Medpace Holdings, I… (MEDP) | 100 | 242.7 | +142.7% |
| IQVIA Holdings Inc. (IQV) | 100 | 73.7 | -26.3% |
| Doximity, Inc. (DOCS) | 100 | 44.7 | -55.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CERT vs VEEV vs MEDP vs IQV vs DOCS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Among these 5 stocks, CERT doesn't own a clear edge in any measured category.
VEEV ranks third and is worth considering specifically for income & stability and sleep-well-at-night.
- beta 0.77
- Lower volatility, beta 0.77, Low D/E 1.3%, current ratio 4.89x
- Beta 0.77, current ratio 4.89x
- Beta 0.77 vs IQV's 1.33, lower leverage
MEDP has the current edge in this matchup, primarily because of its strength in long-term compounding.
- 14.4% 10Y total return vs VEEV's 5.2%
- +42.9% vs DOCS's -55.4%
- 24.8% ROA vs CERT's -0.1%, ROIC 154.9% vs 1.5%
IQV is the clearest fit if your priority is value.
- Lower P/E (14.1x vs 25.2x), PEG 0.35 vs 0.79
DOCS is the #2 pick in this set and the best alternative if growth exposure and valuation efficiency is your priority.
- Rev growth 20.0%, EPS growth 54.2%, 3Y rev CAGR 18.4%
- PEG 0.21 vs VEEV's 1.04
- 20.0% revenue growth vs IQV's 5.9%
- 37.5% margin vs CERT's -0.4%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 20.0% revenue growth vs IQV's 5.9% | |
| Value | Lower P/E (14.1x vs 25.2x), PEG 0.35 vs 0.79 | |
| Quality / Margins | 37.5% margin vs CERT's -0.4% | |
| Stability / Safety | Beta 0.77 vs IQV's 1.33, lower leverage | |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | +42.9% vs DOCS's -55.4% | |
| Efficiency (ROA) | 24.8% ROA vs CERT's -0.1%, ROIC 154.9% vs 1.5% |
CERT vs VEEV vs MEDP vs IQV vs DOCS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
CERT vs VEEV vs MEDP vs IQV vs DOCS — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
MEDP leads in 2 of 6 categories
DOCS leads 1 • CERT leads 1 • VEEV leads 0 • IQV leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
DOCS leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
IQV is the larger business by revenue, generating $16.6B annually — 39.7x CERT's $419M. DOCS is the more profitable business, keeping 37.5% of every revenue dollar as net income compared to CERT's -0.4%. On growth, MEDP holds the edge at +26.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $419M | $3.2B | $2.7B | $16.6B | $638M |
| EBITDAEarnings before interest/tax | $78M | $956M | $577M | $3.5B | $250M |
| Net IncomeAfter-tax profit | -$2M | $909M | $460M | $1.4B | $239M |
| Free Cash FlowCash after capex | $67M | $1.4B | $745M | $2.7B | $314M |
| Gross MarginGross profit ÷ Revenue | +61.5% | +75.5% | +29.1% | +26.1% | +89.7% |
| Operating MarginEBIT ÷ Revenue | +5.0% | +28.7% | +21.0% | +13.9% | +37.4% |
| Net MarginNet income ÷ Revenue | -0.4% | +28.4% | +17.2% | +8.3% | +37.5% |
| FCF MarginFCF ÷ Revenue | +15.9% | +43.7% | +27.8% | +16.1% | +49.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +3.3% | +16.0% | +26.5% | +8.4% | +9.8% |
| EPS Growth (YoY)Latest quarter vs prior year | -191.0% | +23.9% | +16.6% | +15.0% | -16.2% |
Valuation Metrics
CERT leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 22.8x trailing earnings, IQV trades at a 26% valuation discount to VEEV's 30.9x P/E. Adjusting for growth (PEG ratio), DOCS offers better value at 0.30x vs VEEV's 1.70x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $1.0B | $27.4B | $12.2B | $30.3B | $5.2B |
| Enterprise ValueMkt cap + debt − cash | $857M | $26.0B | $12.0B | $44.5B | $5.0B |
| Trailing P/EPrice ÷ TTM EPS | -631.00x | 30.92x | 28.06x | 22.79x | 23.45x |
| Forward P/EPrice ÷ next-FY EPS est. | 14.10x | 18.98x | 25.24x | 14.06x | 16.83x |
| PEG RatioP/E ÷ EPS growth rate | — | 1.70x | 0.88x | 0.56x | 0.30x |
| EV / EBITDAEnterprise value multiple | 11.05x | 28.40x | 21.31x | 12.97x | 21.14x |
| Price / SalesMarket cap ÷ Revenue | 2.47x | 8.56x | 4.84x | 1.86x | 9.18x |
| Price / BookPrice ÷ Book value/share | 0.95x | 3.89x | 27.57x | 4.67x | 4.84x |
| Price / FCFMarket cap ÷ FCF | 10.94x | 19.33x | 17.96x | 14.78x | 19.64x |
Profitability & Efficiency
MEDP leads this category, winning 4 of 8 comparable metrics.
Profitability & Efficiency
MEDP delivers a 120.9% return on equity — every $100 of shareholder capital generates $121 in annual profit, vs $-0 for CERT. CERT carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to IQV's 2.44x. On the Piotroski fundamental quality scale (0–9), DOCS scores 9/9 vs IQV's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -0.2% | +13.4% | +120.9% | +22.1% | +24.4% |
| ROA (TTM)Return on assets | -0.1% | +11.1% | +24.8% | +4.7% | +20.7% |
| ROICReturn on invested capital | +1.5% | +12.9% | +154.9% | +8.7% | +20.0% |
| ROCEReturn on capital employed | +1.5% | +13.8% | +65.7% | +11.0% | +22.3% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 6 | 6 | 4 | 9 |
| Debt / EquityFinancial leverage | 0.01x | 0.01x | 0.55x | 2.44x | 0.01x |
| Net DebtTotal debt minus cash | -$178M | -$1.3B | -$247M | $14.2B | -$197M |
| Cash & Equiv.Liquid assets | $189M | $1.4B | $497M | $2.0B | $210M |
| Total DebtShort + long-term debt | $11M | $96M | $250M | $16.2B | $12M |
| Interest CoverageEBIT ÷ Interest expense | — | — | — | 3.10x | — |
Total Returns (Dividends Reinvested)
MEDP leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MEDP five years ago would be worth $25,938 today (with dividends reinvested), compared to $2,141 for CERT. Over the past 12 months, MEDP leads with a +42.9% total return vs DOCS's -55.4%. The 3-year compound annual growth rate (CAGR) favors MEDP at 27.0% vs CERT's -35.4% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -27.8% | -23.4% | -24.9% | -20.7% | -39.9% |
| 1-Year ReturnPast 12 months | -44.9% | -29.4% | +42.9% | +16.5% | -55.4% |
| 3-Year ReturnCumulative with dividends | -73.1% | -5.2% | +104.6% | -5.9% | -24.2% |
| 5-Year ReturnCumulative with dividends | -78.6% | -35.3% | +159.4% | -23.8% | -50.9% |
| 10-Year ReturnCumulative with dividends | -83.4% | +519.4% | +1442.7% | +166.5% | -50.9% |
| CAGR (3Y)Annualised 3-year return | -35.4% | -1.8% | +27.0% | -2.0% | -8.8% |
Risk & Volatility
Evenly matched — VEEV and IQV each lead in 1 of 2 comparable metrics.
Risk & Volatility
VEEV is the less volatile stock with a 0.77 beta — it tends to amplify market swings less than IQV's 1.33 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IQV currently trades 72.3% from its 52-week high vs DOCS's 34.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.21x | 0.77x | 1.26x | 1.33x | 1.03x |
| 52-Week HighHighest price in past year | $13.88 | $310.50 | $628.92 | $247.05 | $76.51 |
| 52-Week LowLowest price in past year | $5.19 | $148.05 | $284.48 | $134.65 | $20.55 |
| % of 52W HighCurrent price vs 52-week peak | +45.5% | +54.2% | +68.2% | +72.3% | +34.0% |
| RSI (14)Momentum oscillator 0–100 | 53.5 | 49.6 | 40.6 | 58.5 | 60.1 |
| Avg Volume (50D)Average daily shares traded | 3.5M | 2.3M | 371K | 1.6M | 2.7M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: CERT as "Buy", VEEV as "Buy", MEDP as "Hold", IQV as "Buy", DOCS as "Buy". Consensus price targets imply 66.5% upside for VEEV (target: $280) vs 16.4% for MEDP (target: $499).
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Hold | Buy | Buy |
| Price TargetConsensus 12-month target | $10.00 | $280.10 | $498.86 | $225.63 | $42.79 |
| # AnalystsCovering analysts | 14 | 42 | 19 | 44 | 22 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | 2 | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +4.1% | +0.6% | +7.5% | +4.1% | +2.3% |
MEDP leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). DOCS leads in 1 (Income & Cash Flow). 1 tied.
CERT vs VEEV vs MEDP vs IQV vs DOCS: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is CERT or VEEV or MEDP or IQV or DOCS a better buy right now?
For growth investors, Doximity, Inc.
(DOCS) is the stronger pick with 20. 0% revenue growth year-over-year, versus 5. 9% for IQVIA Holdings Inc. (IQV). IQVIA Holdings Inc. (IQV) offers the better valuation at 22. 8x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate Certara, Inc. (CERT) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CERT or VEEV or MEDP or IQV or DOCS?
On trailing P/E, IQVIA Holdings Inc.
(IQV) is the cheapest at 22. 8x versus Veeva Systems Inc. at 30. 9x. On forward P/E, IQVIA Holdings Inc. is actually cheaper at 14. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Doximity, Inc. wins at 0. 21x versus Veeva Systems Inc. 's 1. 04x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — CERT or VEEV or MEDP or IQV or DOCS?
Over the past 5 years, Medpace Holdings, Inc.
(MEDP) delivered a total return of +159. 4%, compared to -78. 6% for Certara, Inc. (CERT). Over 10 years, the gap is even starker: MEDP returned +1443% versus CERT's -83. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CERT or VEEV or MEDP or IQV or DOCS?
By beta (market sensitivity over 5 years), Veeva Systems Inc.
(VEEV) is the lower-risk stock at 0. 77β versus IQVIA Holdings Inc. 's 1. 33β — meaning IQV is approximately 72% more volatile than VEEV relative to the S&P 500. On balance sheet safety, Certara, Inc. (CERT) carries a lower debt/equity ratio of 1% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — CERT or VEEV or MEDP or IQV or DOCS?
By revenue growth (latest reported year), Doximity, Inc.
(DOCS) is pulling ahead at 20. 0% versus 5. 9% for IQVIA Holdings Inc. (IQV). On earnings-per-share growth, the picture is similar: Certara, Inc. grew EPS 86. 7% year-over-year, compared to 4. 7% for IQVIA Holdings Inc.. Over a 3-year CAGR, MEDP leads at 20. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — CERT or VEEV or MEDP or IQV or DOCS?
Doximity, Inc.
(DOCS) is the more profitable company, earning 39. 1% net margin versus -0. 4% for Certara, Inc. — meaning it keeps 39. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DOCS leads at 39. 9% versus 5. 0% for CERT. At the gross margin level — before operating expenses — DOCS leads at 90. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is CERT or VEEV or MEDP or IQV or DOCS more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Doximity, Inc. (DOCS) is the more undervalued stock at a PEG of 0. 21x versus Veeva Systems Inc. 's 1. 04x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, IQVIA Holdings Inc. (IQV) trades at 14. 1x forward P/E versus 25. 2x for Medpace Holdings, Inc. — 11. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for VEEV: 66. 5% to $280. 10.
08Which pays a better dividend — CERT or VEEV or MEDP or IQV or DOCS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is CERT or VEEV or MEDP or IQV or DOCS better for a retirement portfolio?
For long-horizon retirement investors, Medpace Holdings, Inc.
(MEDP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26), +1443% 10Y return). Both have compounded well over 10 years (MEDP: +1443%, CERT: -83. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between CERT and VEEV and MEDP and IQV and DOCS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: CERT is a small-cap quality compounder stock; VEEV is a mid-cap high-growth stock; MEDP is a mid-cap high-growth stock; IQV is a mid-cap quality compounder stock; DOCS is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.